NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$80.89
-2.60 (-3.11%)
Close of Nov 06, 2026 · end-of-day data
LMAT 8-K filings in 2026
Every material Form 8-K LeMaitre Vascular filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LeMaitre reported preliminary third-quarter 2026 sales of $68.0 million, up 11% from a year earlier, while diluted EPS fell 14% to $0.65 and operating income fell 13% to $17.7 million. The company kept its full-year 2026 outlook, guiding to sales of $274.8 million to $276.8 million and EPS of $2.77 to $2.82, and declared a $0.25 quarterly dividend. The company also bought certain vascular assets from B. Braun for $19.2 million in October.
Q3 2026 net sales $68.0 million, up 11% (12% organic) from Q3 2025; diluted EPS $0.65 versus $0.75
Q3 operating income $17.7 million versus $20.3 million a year earlier; the prior-year period included a $3.4 million employee retention tax credit benefit
FY 2026 guidance: sales $274.8 million to $276.8 million and EPS $2.77 to $2.82; Q4 EPS guidance $0.70 to $0.75
Quarterly dividend of $0.25 per share payable December 3, 2026, to holders of record on November 19, 2026
LeMaitre Vascular reported preliminary Q2 2026 results with net sales of $70.4 million, up 10% from a year earlier, and operating income of $20.4 million, up 26%. The company also gave guidance: full-year 2026 sales of $274.3 million to $278.3 million and diluted EPS of $2.84 to $2.94, while third-quarter operating income and EPS are guided below last year's levels, which included a one-time employee retention tax credit benefit.
Q2 2026 net sales $70.4 million, up 10%; gross margin 72.1%, up 210 basis points; diluted EPS $0.74, up 23% from $0.60.
Full-year 2026 guidance: sales $274.3 million to $278.3 million; EPS $2.84 to $2.94, midpoint up 15% from 2025 as reported.
Q3 2026 guidance: EPS $0.66 to $0.71 and operating income $17.3 million to $18.8 million, both below Q3 2025 as reported, which included an employee retention tax credit benefit.
Board approved a quarterly dividend of $0.25 per share, payable September 3, 2026, to holders of record on August 20, 2026.
LeMaitre Vascular reported preliminary first-quarter 2026 results, with net sales up 11% to $66.6 million and diluted EPS up 42% to $0.68 from a year earlier. Management said full-year 2026 guidance was increased, now projecting sales of $277 million to $283 million and EPS of $2.93 to $3.08.
Q1 2026 net sales of $66.6 million, up 11% (10% organic) versus Q1 2025; gross margin 72.7%, up 350 basis points
Q1 2026 diluted EPS of $0.68 versus $0.48 in Q1 2025; income from operations of $17.8 million, up 41%
Full-year 2026 guidance: sales of $277 million to $283 million and EPS of $2.93 to $3.08; Q2 2026 sales guidance of $70.5 million to $72.5 million
Quarterly dividend of $0.25 per share, payable June 4, 2026 to holders of record on May 21, 2026
LeMaitre Vascular director Bridget Ross notified the board on April 8, 2026 that she will not stand for re-election at the June 2, 2026 annual meeting, and she will serve until then. The board nominated David B. Roberts for a Class II seat to rebalance board classes; he conditionally resigned his Class I seat, and the board will shrink from eight to seven members. The filing describes these changes as administrative and states no disagreements with the company.
Bridget Ross, Class II director, notified the board on April 8, 2026 of her intent not to stand for re-election
David B. Roberts nominated as Class II director; he notified the board on April 9, 2026 of his conditional resignation as a Class I director
Board size reduced from eight to seven members, effective upon Ross's departure; board to have two Class I, two Class II and three Class III directors
LeMaitre Vascular reported preliminary fourth-quarter 2025 sales of $64.5 million, up 16%, with operating income of $18.8 million, up 47%. The company also guided to 2026 full-year sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01, and raised its quarterly dividend 25% and authorized a $100.0 million share repurchase program.
Q4 2025 diluted EPS was $0.68, up 39% from the prior-year quarter, and gross margin was 71.7%, up 240 basis points.
Full-year 2026 guidance calls for sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01.
On February 19, 2026, the board raised the quarterly dividend 25% to $0.25 per share, payable March 26, 2026, and authorized up to $100.0 million in buybacks through February 18, 2027.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LeMaitre Vascular filing is on SEC EDGAR ↗. 8-K briefs of other companies →